Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04409639

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations — CONCERTO  

Chronic Myelomonocytic Leukemia (CMML) Clinical Trial

Official title:
Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Clinical Trial Summary

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met.

Clinical Trial Description

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. Two cohorts of patients will be accrued using Simon's two-stage design (Simon, 1989) for both cohorts. Cohort 1 will enroll nine newly diagnosed patients in the first stage and if four or more responses are observed five additional patients will be enrolled in the second stage. Cohort 2 will enroll six HMA refractory patients in the first stage and if one or more responses are observed then nine additional patients will be enrolled in the second stage. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered consecutively for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met. ;

Study Design

Related Conditions & MeSH terms

  • Chronic Myelomonocytic Leukemia (CMML)
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myelomonocytic, Juvenile
Clinical Trial Details
NCT number NCT04409639
Study type Interventional
Source University of Utah
Contact Braxton Smith
Phone 801-213-8431
Email Braxton.Smith@hci.utah.edu
Status Recruiting
Phase Phase 2
Start date January 12, 2021
Completion date August 15, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00528983 - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Phase 1
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Completed NCT01736683 - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Phase 2
Terminated NCT02147873 - Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Phase 2
Completed NCT02546284 - Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Phase 1
Terminated NCT02749708 - Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04603001 - Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Phase 1
Completed NCT01842646 - Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT01613976 - A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients Phase 1
Terminated NCT00664677 - Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia Phase 1
Recruiting NCT03922100 - Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Phase 1/Phase 2
Completed NCT05048498 - Pharmacokinetics, Tolerability and Safety of NEX-18a Phase 1
Withdrawn NCT04217720 - SNS-301 Monotherapy in High Risk MDS and CMML Phase 2